Weekly Pharma & Life Science News Round-Up: 14th – 18th November
A round-up of the latest news from the Pharma & Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 14th-18th November.
Avanzanite Bioscience B.V. officially launches its commercial-stage enterprise, seeking to expand patient access to medicines for rare diseases in Europe while unlocking revenue and growth potential for emerging research-based biopharmaceutical originators.
Velocity Clinical Research expands to UK
Velocity Clinical Research (“Velocity”), the leading integrated research site organisation, announces its expansion into the U.K. with the acquisition of multi-site company Egin Research.
GSK tops Access to Medicine Index (ATMI) for eighth consecutive time
GSK ranks 1st in the 2022 Access to Medicine Index (ATMI) report. The Index is an independent, investor-backed report that ranks 20 of the world’s largest pharmaceutical companies on progress to improve access in 108 lower income countries and focuses on 83 high burden priority diseases.
Developing new antibiotics key for the race against resistant infections says ABPI
This year’s World Antimicrobial Awareness Week aims to improve the awareness and understanding of antimicrobial resistance (AMR). The event seeks to encourage best practices among the public, health workers and policy makers to avoid the further emergence and spread of antibiotic resistance.
Viatris Inc. a global healthcare company, announced that it intends to create an ophthalmology franchise by acquiring Oyster Point Pharma and Famy Life Sciences.
Advanced Clinical Launches Refreshed Brand and Website
Advanced Clinical, a privately-held clinical research services organization committed to providing a better clinical experience across the drug development journey, is pleased to announce a refreshed brand and new website.
Eremid® Genomic Services receives CLIA accreditation for its new clinical genomics laboratory
Eremid® Genomic Services, LLC (“Eremid”) announces that it has been granted a Clinical Laboratory Improvement Amendments (CLIA) accreditation for its new laboratory dedicated to analyzing human clinical samples.
Researchers make miniature ‘bone marrows in a dish’ to improve anti-cancer treatments
Scientists from Oxford University and the University of Birmingham have made the first bone marrow ‘organoids’ that capture the key features of human bone marrow. The technology will allow for the screening of multiple anti-cancer drugs at the same time.
Edmund Optics© Announces 2022 Educational Award and Norman Edmund Award Recipients
Edmund Optics®, a leading global manufacturer and supplier of optical components, announces the recipients of its 2022 Educational Award program. This award is given in recognition of outstanding undergraduate and graduate optics research in science, technology, engineering, and mathematics.
PAION AG enters partnership with Viatris and expands sales activities in Europe
PAION AG has entered into a long-term collaboration with Mylan Ireland Limited, a subsidiary of the Viatris Group, for the distribution in both Southern Europe and other European countries which are not currently served by PAION or its other distribution partner Medis.
Growth in UK cell and gene therapy manufacturing capacity and employment continues
The Cell and Gene Therapy Catapult (CGT Catapult) published its ninth annual UK cell and gene therapy Good Manufacturing Practice (GMP) manufacturing report, showing continued growth in the Advanced Therapy Medicinal Products (ATMP) UK manufacturing sector.
Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
Synaffix B.V. announces the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of November at the Old Billingsgate in London, UK.
New personalised cancer medicine company moves in at The London Cancer Hub’s Innovation Gateway
Personalised cancer medicine start-up Curesponse has become the latest MedTech company to move in at the Innovation Gateway at The London Cancer Hub in Sutton, south London.
Ablexis, LLC (“Ablexis”) and AlivaMab Discovery Services, LLC (“ADS”) announces an expansion of platforms and capabilities in antibody drug discovery and engineering.
atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders announces it has initiated a clinical study with Massachusetts General Hospital (MGH).
